
Reka Toth
Articles
-
Nov 11, 2024 |
biorxiv.org | Anna Niehues |Lukas Najdekr |Reka Toth |Casper Visser
AbstractMulti-omics investigations hold promise for uncovering biomarker profiles crucial for disease diagnosis, prognosis, and monitoring interventions. However, these profiles are susceptible to technical and biological variation. Capturing biological variability and removing technical variability are essential for future studies.
-
Mar 18, 2024 |
biorxiv.org | Maria Font Farre |Daniel Brown |Reka Toth |Chidambareswaren Mahadevan
AbstractEukaryotes produce a large number of cytochrome P450s that mediate the synthesis and degradation of diverse endogenous and exogenous metabolites. Yet, most of these P450s are uncharacterized and global tools to study these challenging, membrane-resident enzymes remain to be exploited. Here, we applied activity profiling of plant, mouse and fungal P450s with chemical probes that become reactive when oxidized by P450 enzymes.
-
Jan 16, 2024 |
gut.bmj.com | Reka Toth |Paul Brindley |Javier Vaquero |CSIC-Universidad de Salamanca
Enhancing the opportunities for cholangiocarcinoma precision therapy Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
-
Mar 22, 2023 |
nature.com | Dieter Weichenhan |Reka Toth |Pavlo Lutsik |Joschka Hey |Etienne Sollier |Aurore Touzart | +3 more
To the Editor:Recurrent translocations are common in acute myeloid leukemia (AML) and important for cytogenetic classification and prognosis [1]. AML-derived leukemic cell lines have been essential to study molecular defects and to develop novel therapeutic approaches [2, 3]. The leukemic cell line GDM-1 was established from a patient with acute myelomonoblastic leukemia [4].
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →